English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04396860 /

NRG-BN007

A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Actively Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

DISEASE GROUP:
Neuro-Oncology
current phase:
Phase II/III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: